Pulmonary hypertension

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 20-25

  Peacock, Andrew ^a  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

End points; Epidemiology; Pathobiology; Pulmonary hypertension; Treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DASATINIB; ENDOTHELIN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; MICRORNA; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; SIMVASTATIN; WARFARIN;

DEVELOPING COUNTRY; DISEASE CLASSIFICATION; EPIGENETICS; EXERCISE TEST; FIBROGENESIS; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; IRON DEFICIENCY; KINESIOTHERAPY; MESENCHYMAL STEM CELL; NONHUMAN; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SEX DIFFERENCE; SURVIVAL; SYSTEMIC SCLEROSIS; VASCULITIS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84874748807     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006912     Document Type: Review

References (31)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl., S43-S54.
2. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology and survival of incident pulmonary arterial hypertension: results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-796.
3. de Jesus Perez VA, Haddad F, Zamanian RT. Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction. Pulm Circ 2012; 2: 163-169.
4. Park MH, Mehra MR. Pulmonary hypertension. The great leveller. J Am Coll Cardiol 2012; 59: 232-234.
5. Hassoun PM, Adnot S. Update in pulmonary vascular diseases 2011. Am J Respir Crit Care Med 2012; 185: 1177-1182.
6. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164-174.
7. Fonseca GHH, Souza R, Salemi VMC, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39: 112-118.
8. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by Dasatinib. Circulation 2012; 125: 2128-2137.
9. Yeager ME, Nguyen CM, Belchenko DD, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J 2012; 39: 104-111.
10. Toshner MR, Morrell NW. The fibrocyte in pulmonary hypertension: we seek him here, we seek him there. Eur Respir J 2012; 39: 5-6.
11. Umar S, Rabinovitch M, Eghbali M. Estrogen paradoxinpulmonary hypertension. Am J Respir Crit Care Med 2012; 186: 125-131.
12. Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence outcomes, and mechanistic insights. J Am Coll Cardiol 2011; 58: 300-309.
13. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 210-221.
14. Thermo Scientific. shMIMIC Lentiviral microRNA. Supporting data, figure 1: over expression of mature microRNA results in gene modulation. www.thermoscientificbio.com/microrna/ shmimic-lentiviral-microrna/
15. Qui J. Epigenetics: Unfinished symphony. Nature 2006; 441: 143-145.
16. Suárez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009; 104: 442-454.
17. Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208: 535-548.
18. Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Cell Mol Biol 2012; 185: 409-419.
19. Cool CD, Groshong SD, Oakey J, et al. Pulmonary hypertension: cellular and molecular mechanisms. Chest 2005; 128: Suppl. 6, 565S-571S.
20. Abe K, Toba M, Alzoubi A, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 2011; 45: 804-808.
21. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261-272.
22. Pogoriler JE, Rich S, Archer SL, et al. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology 2012; 61: 597-609.
23. Grünig E, Lichtblau M, Ehlken N, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 2012; 40: 84-92.
24. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-1645.
25. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a Treatment for Pulmonary Hypertension Trial (SiPHT). Am J Respir Crit Care Med 2010; 181: 1110-1112.
26. Carlin C, Celnick DF, Pak O, et al. Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. Am J Respir Cell Mol Biol 2012; 46: 1-9.
27. Johnson SR, Granton JT, Tomlinson GA, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39: 276-285.
28. van de Veerdonk MC, Kind T, Marcus JT. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2516-2517.
29. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
30. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial trials. Circulation 2012; 126: 349-356.
31. 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: 670-679.